The expression of PD-L1 assessed by immunohistochemistry has been shown to correlate with the response to ICIs in several tumor types, and Gani and colleagues evaluated that iCCAs expressing PD-L1 in the TF had a 60% reduced survival compared with PD-L1-negative patients (56). This evidence concerns the gene CD274 and neoplasm.